Drug intelligence / Profile preview

BB708B Metabolite 2

Development stage: Unknown
Lead developer: BalinBac Therapeutics
Modality: Small Molecules
Administration: Inhalation, Oral

Overview

**BB708B Metabolite 2** is a purported BalinBac Therapeutics COVID-19 candidate associated with the company’s BB-700-series repurposed-drug program. BalinBac describes the BB-700 series generally as multi-active combinations of available generic drugs intended to apply complementary antiviral mechanisms, with oral and inhalation delivery approaches. However, no public source located during review identified the composition, chemical identity, metabolite parent compound, specific mechanism, clinical study, regulatory authorization, or manufacturing details for the exact name **BB708B Metabolite 2**.

Beyond the preview

Go deeper on BB708B Metabolite 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BB708B Metabolite 2.

Explore the full profile